Meloxicam
- Generic Name
- Meloxicam
- Brand Names
- Anjeso, Mobic, Qmiiz, Vivlodex
- Drug Type
- Small Molecule
- Chemical Formula
- C14H13N3O4S2
- CAS Number
- 71125-38-7
- Unique Ingredient Identifier
- VG2QF83CGL
- Background
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.
- Indication
Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain.
Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
- Associated Conditions
- Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis
- Conditions
- Pharyngitis
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 390
- Registration Number
- NCT02183038
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 82
- Registration Number
- NCT02183155
Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02181322
Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9984
- Registration Number
- NCT02180516
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's LymphomaMultiple Myeloma
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Sherif S. Farag
- Target Recruit Count
- 38
- Registration Number
- NCT02078102
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- University of Stellenbosch
- Target Recruit Count
- 200
- Registration Number
- NCT02060006
- Locations
- 🇿🇦
Stellenbosch University Tygerberg Hospital, Cape Town, Western Cape Province, South Africa
Meloxicam vs Placebo for Mobilization
- Conditions
- Hodgkin's LymphomaMultiple MyelomaNon-Hodgkin's LymphomaHematopoietic Stem Cells
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT02003625
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women
- Conditions
- ContraceptionBleeding Pattern
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Laboratorios Andromaco S.A.
- Target Recruit Count
- 13
- Registration Number
- NCT01839643
- Locations
- 🇨🇱
Instituto Chileno de Medicina Reproductiva (ICMER), Santiago, Chile
Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Iroko Pharmaceuticals, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT01801735
Discontinuing NSAIDs in Veterans With Knee Osteoarthritis
- Conditions
- Knee Osteoarthritis
- Interventions
- Behavioral: Cognitive Behavioral Therapy
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 490
- Registration Number
- NCT01799213
- Locations
- 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States
🇺🇸Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States
🇺🇸VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.